UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 20, 2020

 

Osmotica Pharmaceuticals plc

(Exact name of registrant as specified in its charter)

 

Ireland   001-38709   Not Applicable
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

400 Crossing Boulevard
Bridgewater, NJ
  08807
(Address of principal executive offices)   (Zip Code)

 

(Registrant’s telephone number, including area code): (908) 809-1300

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Ordinary Shares   OSMT   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

At the 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) of Osmotica Pharmaceuticals plc (the “Company”) held on May 20, 2020, shareholders voted on the following proposals:

 

·Election of the directors of the Company, each to serve a term extending until the conclusion of the Company’s next annual general meeting of shareholders;

 

·Ratification, in a non-binding advisory vote, of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2020, and authorization, in a binding vote, of the Company’s board of directors, acting through the audit committee, to set the independent registered public accounting firm’s remuneration; and

 

·Approval of a waiver of offer obligations under Rule 37 of the Irish Takeover Rules to enable share buybacks or redemptions.

 

The final voting results for the Annual Meeting are as follows:

 

1.The shareholders elected Brian Markison, Joachim Benes, David Burgstahler, Gregory L. Cowan, Michael DeBiasi, Sriram Venkataraman, Juan Vergez and Fred Weiss as directors, each to serve a term extending until the conclusion of the Company’s next annual general meeting of shareholders or until his successor is duly elected and qualified or until his death, resignation or removal, based on the following votes:

 

   For   Against   Abstain   Broker
Non-Votes
 
Brian Markison   41,057,347    1,948,306    6,678    6,206,331 
                     
Joachim Benes   41,399,103    1,606,558    6,670    6,206,331 
                     
David Burgstahler   40,227,229    2,778,433    6,669    6,206,331 
                     
Gregory L. Cowan   42,925,631    80,031    6,669    6,206,331 
                     
Michael DeBiasi   42,924,677    80,087    7,567    6,206,331 
                     
Sriram Venkataraman   41,393,754    1,606,585    11,992    6,206,331 
                     
Juan Vergez   39,914,896    3,085,443    11,992    6,206,331 
                     
Fred Weiss   41,575,173    1,425,246    11,912    6,206,331 

 

2.The shareholders ratified, in a non-binding advisory vote, the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2020, and authorized, in a binding vote, the Company’s board of directors, acting through the audit committee, to set the independent registered public accounting firm’s remuneration, based on the following votes:

 

For   Against   Abstain   Broker Non-Votes 
 49,202,039    11,140    5,483    0 

 

3. The independent shareholders did not approve a waiver of offer obligations under Rule 37 of the Irish Takeover Rules to enable share buybacks or redemptions, based on the following votes:

 

For   Against   Abstain   Broker Non-Votes 
 2,867,646    3,050,625    74,490    6,206,331 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OSMOTICA PHARMACEUTICALS PLC
     
  By: /s/ Andrew Einhorn
    Andrew Einhorn
    Chief Financial Officer

 

Date: May 27, 2020